Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Advanced Solid Tumor 4Solid Tumor 3Advanced Solid Tumors 2Locally Advanced or Metastatic Solid Tumors 1Advanced Malignant Solid Tumor 1

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4spartalizumab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3Midazolam 3Itraconazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Solid Tumor × camrelizumab × Other solid neoplasm × Clear all
NCT04346381 2023-09-18

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
233 enrolled
Other solid neoplasm

Solid Tumor

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
31 enrolled
Other solid neoplasm

Solid Tumor

NCT04832204 2021-04-05

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Beijing Hospital

Phase 2 Unknown
20 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡